Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $20.14 Average PT from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $18.75.

A number of analysts have commented on the company. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. cut their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the transaction, the chief executive officer owned 340,106 shares in the company, valued at $1,935,203.14. This trade represents a 13.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 59,644 shares of company stock worth $336,462. 2.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC lifted its position in shares of Lexeo Therapeutics by 57.8% during the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after buying an additional 1,850,211 shares during the period. RA Capital Management L.P. bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth approximately $49,650,000. Paradigm Biocapital Advisors LP bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth approximately $47,299,000. Vestal Point Capital LP raised its position in Lexeo Therapeutics by 37.7% in the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock valued at $44,437,000 after purchasing an additional 1,225,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Lexeo Therapeutics in the 2nd quarter valued at $16,117,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Trading Down 3.9%

Shares of LXEO stock opened at $4.70 on Friday. The stock has a 50 day moving average of $5.29 and a two-hundred day moving average of $6.77. Lexeo Therapeutics has a 12 month low of $3.60 and a 12 month high of $10.99. The company has a market capitalization of $369.04 million, a P/E ratio of -3.24 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Sell-side analysts predict that Lexeo Therapeutics will post -1.23 earnings per share for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.